M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer ...